Biotech Values

[oc631]

I think we can already say that the warehouse effect touted by VRTX (and to a lesser extent by MRK) has been overrated to some degree. Still, the first-year sales numbers for Incivek are going to look pretty good compared to almost any recent launch in the drug/biotech industry.

The promise of interferon-free treatment should keep the majority of HCV patients "sitting in the warehouse". The fact that HCV does it's damage over the course of decades was once reason to sit and wait for Incivek. It seems like that line of thinking has come full circle.